Prescription Wearables Target ‘Pre-Disease’ Gap in Aging Care

A growing number of healthtech companies are targeting a long-overlooked segment of care: patients who are no longer fully healthy but not yet eligible for pharmaceutical treatment. This “pre-disease” category includes conditions such as low bone density, early metabolic dysfunction, and age-related physical decline—areas where the standard of care often remains limited to lifestyle advice.

One example is Osteoboost Health, which recently raised $8 million to scale a prescription wearable designed to treat osteopenia. The FDA-cleared device delivers vibration therapy to reduce bone density loss, positioning itself as a regulated intervention between consumer wellness products and traditional drug therapies.

This approach reflects a broader shift toward clinical-grade, non-pharmacological treatments that can be deployed earlier in the patient journey. Rather than waiting for disease progression, these solutions aim to intervene when decline is measurable but still reversible, a model that aligns with the increasing focus on healthspan and preventative care.

The same dynamic is visible across men’s health. Conditions such as low testosterone, early-stage muscle loss, and cardiometabolic risk often fall into a similar treatment gap, where patients experience symptoms but do not meet the threshold for clinical intervention. As a result, companies are beginning to explore alternatives that sit between lifestyle optimisation and prescription drugs.

For investors and operators, the opportunity comes with trade-offs. Preventative solutions have the potential to reduce long-term healthcare costs, but face challenges around reimbursement, clinical adoption, and patient adherence. As more companies move into this space, the ability to demonstrate real-world outcomes—and secure payer support—will likely determine which models scale.